4TZ Stock Overview
A clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
ORIC Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.30 |
| 52 Week High | US$14.80 |
| 52 Week Low | US$6.15 |
| Beta | 1.12 |
| 11 Month Change | 20.78% |
| 3 Month Change | 3.91% |
| 1 Year Change | 38.81% |
| 33 Year Change | -28.46% |
| 5 Year Change | n/a |
| Change since IPO | -61.62% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4TZ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 20.8% | -0.2% | 0.8% |
| 1Y | 38.8% | -16.9% | 9.1% |
Return vs Industry: 4TZ exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 4TZ exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 4TZ volatility | |
|---|---|
| 4TZ Average Weekly Movement | 10.5% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4TZ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 4TZ's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 112 | Jacob Chacko | www.oricpharma.com |
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms, including ORIC-613, an orally bioavailable, highly selective inhibitor of PLK4, in preclinical studies for the treatment of breast cancers.
ORIC Pharmaceuticals, Inc. Fundamentals Summary
| 4TZ fundamental statistics | |
|---|---|
| Market cap | €644.80m |
| Earnings (TTM) | -€114.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-5.8x
P/E RatioIs 4TZ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4TZ income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$119.87m |
| Earnings | -US$119.87m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.70 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 4TZ perform over the long term?
See historical performance and comparison